- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Arcellx-Direktorin Kavita Patel verkauft Aktien im Wert von 159.495 US-Dollar | - | Investing.com Deutsch | ||
| 08.11. | Analyst Expectations For Arcellx's Future | 2 | Benzinga.com | ||
| 08.11. | Arcellx GAAP EPS of -$0.48, revenue of $26.03M | 1 | Seeking Alpha | ||
| 07.11. | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | 47 | Business Wire | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| 07.11. | Arcellx, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11. | Arcellx stock soars to all-time high of $97.61 amid robust growth | 2 | Investing.com | ||
| 07.11. | Arcellx-Aktie erreicht Allzeithoch von 97,61 US-Dollar | 3 | Investing.com Deutsch | ||
| 06.11. | Navigating 7 Analyst Ratings For Arcellx | 1 | Benzinga.com | ||
| ARCELLX Aktie jetzt für 0€ handeln | |||||
| 06.11. | Arcellx to present positive data on multiple myeloma treatments | 1 | PharmaTimes | ||
| 05.11. | ASH: New Gilead-Arcellx data build CAR-T's case against Carvykti in advanced multiple myeloma | 11 | FierceBiotech | ||
| 05.11. | BofA raises Arcellx price target to $100 on positive data | 2 | Investing.com | ||
| 05.11. | BofA erhöht Kursziel für Arcellx auf 100 US-Dollar aufgrund positiver Daten | 3 | Investing.com Deutsch | ||
| 05.11. | Cancer cell therapy from Arcellx, Gilead shows promise in early data | 11 | BioPharma Dive | ||
| 05.11. | Arcellx meldet vielversprechende Ergebnisse für Myelom-Behandlung | 1 | Investing.com Deutsch | ||
| 05.11. | Arcellx, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.11. | Arcellx (ACLX) Surged in Q3. Here's Why | 2 | Insider Monkey | ||
| 29.10. | Arcellx shares target increased, Outperform upheld as ASH data release nears | 1 | Investing.com | ||
| 29.10. | Kursziel für Arcellx-Aktien erhöht, Outperform-Einstufung bestätigt vor ASH-Datenveröffentlichung | 1 | Investing.com Deutsch | ||
| 24.10. | Arcellx's SWOT analysis: cell therapy innovator's stock poised for growth | 6 | Investing.com | ||
| 23.10. | Arcellx, Inc. (NASDAQ:ACLX) Director Sells $134,535.00 in Stock | 1 | MarketBeat |
Seite:
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,010 | -1,94 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,391 | +2,62 % | Defence Therapeutics Inc. begrüßt Dr. Svetlana Selivanova, Expertin für Radiopharmazeutika, im Board of Directors | Vancouver, BC, Kanada, 13. November 2024 / IRW-Press / Defence Therapeutics Inc. ("Defence" oder das
"Unternehmen") (CSE: DTC, OTCQB: DTCFF, FWB: DTC), ein kanadisches biopharmazeutisches Unternehmen... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,000 | -0,83 % | Ginkgo Bioworks Reports Third Quarter 2024 Financial Results | Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions
Ginkgo... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,175 | -10,64 % | Recursion Pharmaceuticals: Recursion and Exscientia Shareholders Approve the Proposed Combination | Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated closeSalt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq:... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,045 | -8,64 % | Beam Therapeutics Inc. Q3 Loss Misses Estimates | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) reported Loss for third quarter that missed the Street estimates.The company's earnings came in at -$96.668 million, or -$1.17 per share.... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,945 | -5,03 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2024 Financial Results and Operational Highlights | BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study
Upcoming... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 16,015 | -12,68 % | ARCT Stock Touches 52-Week Low at $17.26 Amid Market Challenges | ||
| ASSERTIO | 0,810 | -3,57 % | Assertio Holdings, Inc.: Assertio Reports Third Quarter 2024 Financial Results | Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 5,925 | -5,95 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,040 | -5,74 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| VIR BIOTECHNOLOGY | 8,010 | -7,29 % | What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? | ||
| MERRIMACK PHARMACEUTICALS | 15,130 | 0,00 % | MERRIMACK PHARMACEUTICALS INC - 15-12G, Securities registration termination | ||
| VERVE THERAPEUTICS | 4,785 | -11,06 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,200 | +1,78 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| ARVINAS | 22,500 | -9,71 % | Arvinas-Chefbuchhalter David Loomis verkauft Aktien im Wert von 10.300 US-Dollar |
ARCELLX INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 87,83 Euro und damit -7,49 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCELLX INC finden Sie auf Wallstreet Online.
